| Literature DB >> 29067112 |
Xiahong Tang1,2,3, Feng Chen1,2,3, Qinming Lin1,2,3, Yan You1,2,3, Jun Ke1,2,3, Shen Zhao1,2,3.
Abstract
The present study aimed to investigate the beneficial effects and underlying mechanisms of bone marrow mesenchymal stem cells (BMSCs) on global ischemic hypoxic brain injury. Cells collected from the femurs and tibias of male Sprague Dawley rats were used to generate BMSCs following three culture passages. A rate model of cardiac arrest (CA) was induced by asphyxia. One hour following return of spontaneous circulation (ROSC), BMSCs were transplanted through injection into the tail vein. Neurological status was assessed using modified neurological severity score (mNSS) tests 1, 3 and 7 days following ROSC. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and immunohistochemical staining were used to detect insulin-like growth factor 1 (IGF-1) expression in the hippocampus. Furthermore, double-fluorescent labeling of green fluorescent protein (GFP) and IGF-1 was used to detect the IGF-1 expression in transplanted BMSCs. Serum levels of protein S100-B were examined using ELISA. GFP-labeled BMSCs were observed in the hippocampus at 1, 3 and 7 days post transplantation through fluorescent microscopy. BMSC transplantation resulted in reduced protein S100-B levels. The mNSS of the BMSC-treatment group was significantly reduced compared with that of the CA group. The RT-qPCR analysis and immunohistochemistry results demonstrated that BMSC treatment significantly increased IGF-1 expression in the hippocampus. In addition, the double-fluorescent labeling results demonstrated that transplanted BMSCs expressed IGF-1 in the hippocampus. The results of the present study suggest that BMSC treatment promotes the recovery of cerebral function following CA in rats possibly through the secretion of IGF-1.Entities:
Keywords: BMSCs; IGF-1; cardiac arrest; cerebral resuscitation; global brain ischemia
Year: 2017 PMID: 29067112 PMCID: PMC5647699 DOI: 10.3892/etm.2017.5059
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Modified neurological severity scores.
| Items | Points |
|---|---|
| Motor tests | |
| Raising rat by tail | 3 |
| Flexion of forelimb | 1 |
| Flexion of hindlimb | 1 |
| Head moved >10 to vertical axis within 30 | 1 |
| Placing rat on the floor (normal, 0; maximum, 3) | 3 |
| Normal walk | 0 |
| Inability to walk straight | 1 |
| Circling toward the paretic side | 2 |
| Fall down to the paretic side | 3 |
| Sensory tests | 2 |
| Visual and tactile placing | 1 |
| Proprioceptive test (deep sensory) | 1 |
| Beam balance tests | 6 |
| Grasps side of beam | 1 |
| Hugs the beam and one limb falls down from the beam | 2 |
| Hugs the beam and two limb fall down from the beam, or spin on beam (>60 sec) | 3 |
| Attempt to balance on the beam but fall off (>40 sec) | 4 |
| Attempt to balance on the beam but fall off (>20 sec) | 5 |
| Fall off with no attempt to balance or hand on to the beam | 6 |
| Reflexes (blunt or sharp stimulation) absent of: | 4 |
| Pinna reflex (a head shake when touching the auditory meatus) | 1 |
| Corneal reflex (an eye blink when lightly touching the cornea with cotton | 1 |
| Startle reflex (a motor response to a brief loud paper noise) | 1 |
| Seizures, myoclonus, myodystony | 1 |
| Maximum points | |
Score: 13–18 severe; 7–12 moderate; 1–6 mild injury.
The primers and GAPDH.
| Primer name | Sequence (5′-3′) | Length (bp) |
|---|---|---|
| rat-GAPDH-forward | AGTTCAACGGCACAGTCAAGG | 121 |
| rat-GAPDH-reverse | ACATACTCAGCACCAGCATCAC | |
| rat-IGF1-forward | CTGGTGGACGCTCTTCAGTTC | 156 |
| rat-IGF1-reverse | ACAGTACATCTCCAGCCTCCTC |
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IGF1, Insulin-like growth factor 1.
Thermocycle features for polymerase chain reaction.
| Temperature | Time (sec) | Cycles |
|---|---|---|
| 94°C (pre-degeneration) | 30 | Stage 1 1 cycle |
| 95°C (denature) | 5 | Stage 2 40 cycles |
| 61°C (primer annealing) | 30 | |
| 72°C (extension) | 30 | |
| 95°C | 15 | Melting curve 1 cycle |
| 55°C | 15 | |
| 95°C | 15 |
Figure 1.Bone marrow mesenchymal stem cells labeled with green fluorescent protein 72 h after transfection (magnification, ×200).
Figure 2.Modified neurological severity scores in rats. *P<0.05 vs. sham operation group; #P<0.05 vs. cardiac arrest group. CA, cardiac arrest; BMSCs, bone marrow mesenchymal stem cells.
Figure 3.Levels of S100B in rats. *P<0.05 vs. sham operation group; #P<0.05 vs. cardiac arrest group. CA, cardiac arrest; BMSCs, bone marrow mesenchymal stem cells.
Figure 4.Fluorescence in hippocampus at day 1 after ROSC. The arrows indicate IGF-1-positive bone marrow mesenchymal stem cells. (A) Green and red staining to detect positive cells; (B) red staining to detect IGF-1; (C) green staining to detect green fluorescent protein; (D) blue staining to detect the cell nucleus. Magnification, ×200. ROSC, return of spontaneous circulation; IGF-1, insulin-like growth factor 1.
Figure 6.Fluorescence in hippocampus at day 7 after ROSC. The arrows indicate IGF-1-positive bone marrow mesenchymal stem cells. (A) Green and red staining to detect positive cells; (B) red staining to detect IGF-1; (C) green staining to detect green fluorescent protein; (D) blue staining to detect the cell nucleus. Magnification, ×200. ROSC, return of spontaneous circulation; IGF-1, insulin-like growth factor 1.
Figure 7.The expression of IGF-1 mRNA in sham, CA, BMSCs-treated groups *P<0.05 vs. sham operation group; #P<0.05 vs. cardiac arrest group. IGF-1, insulin-like growth factor 1; CA, cardiac arrest; BMSCs, bone marrow mesenchymal stem cells.
Figure 8.Comparison of the IOD value of IGF-1 in different groups. *P<0.05 vs. sham operation group; #P<0.05 vs. cardiac arrest group. IOD, integrated optical density; IGF-1, insulin-like growth factor 1; CA, cardiac arrest; BMSCs, bone marrow mesenchymal stem cells.
Figure 11.Results of insulin-like growth factor 1 by immunohistochemistry in the hippocampus in the bone marrow mesenchymal stem cell-treated group at days (A) 1, (B) 3 and (C) 7.